Blue Sky Health Sector Stock Volatility Report

Notable Movers & Volatility

The dispersion here is extreme: EBS led at +26.92% ($5.20 → $6.60), closing 84.29% of its range and posting a +22.69% period return, while KPTI fell -42.06% ($2.14 → $1.24) with 115.54% realized volatility — the only name whose realized vol exceeded triple digits. Managed care was the cleanest positive cluster: CNC (+12.65%), HUM (+10.24%), ELV (+9.31%) and CI (+6.83%) all finished in the upper half of their ranges, with CNC (96.99%), CI (95.86%) and ELV (92.07%) closing essentially at their highs.

Options pricing underpriced several moves. UNH was the largest surprise at 2.96x realized-to-implied, followed by SYK (2.74x), EBS (2.61x), ABT (1.98x) and AMGN (1.96x) — the latter two pairing that gap with -13.04% and -15.71% declines. Conversely, high implied vol overstated the action in CDXS (282.81% IV, just 0.30x), ADMA (0.41x), ANAB (0.60x), ADUS (0.63x) and XLV (0.67x).

Weak closes were concentrated in decliners: FUJIF (0.00%), ANAB (6.68%), AMGN (6.78%), MRK (8.87%), ABT (10.57%) and ADMA (10.15%) all finished near period lows.

Broader Market Context

Differential behavior within the sector. The spread between the best and worst performer here approaches 69 percentage points, which is unusually wide for a single sector over roughly two weeks — a sign that "Health Sector" behaved less like one trade and more like several. Managed care and insurers (CNC, HUM, ELV, CI, and to a lesser degree CVS) clustered firmly positive and closed near highs. Large-cap pharma was mixed-to-soft: JNJ and GILD showed positive range expansion but negative or flat period returns, while MRK (-8.44%), ABBV (-7.54%) and BMY (-7.28%) drifted lower. Medtech and devices (SYK -19.91%, ABT -13.04%) and biotech/growth-adjacent names (MRNA, BNTX, TEM, HIMS, QURE, DBVT, KPTI) took the worst of it. The XLV benchmark fell just -6.09% with only 15.10% realized vol, confirming that index-level calm masked violent single-name dispersion.

Rotation vs. idiosyncratic moves. The pattern does not look like a clean defensive rotation into healthcare — if it were, the megacaps and the ETF would have led. Instead, capital appears to have moved *within* the sector: toward cash-flow-visible payers and away from long-duration, unprofitable biotech and high-multiple medtech. That is more consistent with a rate- or risk-sensitive repricing of duration than with a wholesale sector bid. At the same time, the outliers — EBS's +26.92% on 2.61x realized/implied, KPTI's -42.06% with 115.54% realized vol, SYK's -19.91% at 2.74x — carry the signature of stock-specific catalysts rather than a shared macro driver.

Plausible sector-relevant backdrops. Without asserting any specific event, the tape is consistent with several recurring healthcare pressure points:

• Policy and reimbursement headlines — drug pricing, formulary or coverage policy — which typically hit pharma and payers asymmetrically and could explain the payer-vs-pharma split.
• Utilization and medical-cost trend expectations, historically the single largest swing factor for CNC, HUM, ELV, CI and UNH; note UNH moved *opposite* its managed-care peers at 2.96x implied, a divergence that often signals company-level news.
• Clinical, regulatory or M&A catalysts in small-cap biotech, the likeliest driver of the EBS/KPTI/DBVT/QURE tails.
• Rates and risk appetite, which disproportionately compress unprofitable biotech and premium-multiple medtech.